Bristol-myers Squibb Stock News

Bristol Myers Squibb (BMY) closed at $64.91 in the latest trading session, marking a +1.64% move from the prior day.

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PALM BEACH, Fla. , Jan. 27, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018, breast cancer ranks as the fifth leading cause of deaths in women; accounting for 627,000 deaths every year. Moreover, as per estimates of the American Cancer Society, in U.S., 266,120 new cases were expected to be diagnosed in women by 2018. Furthermore, aging is considered as one of the greatest risk factors. According to Cancer Treatment Centers of America, women above 60 years of age are more likely to be diagnosed and only about 10% to 15% of cases occur in women younger than 45 years of age. High prevalence of the disease coupled with patent expiry are some of the major factors influencing investment in research and development of new products. The R&D spending from companies like Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Celgene Corporation; Pfizer, Inc.; GlaxoSmithKline plc; Sanofi; and AbbVie, Inc. has increased exponentially.

The big drugmaker is gaining access to Century Therapeutics'' off-the-shelf CAR-T programs.

The big drugmaker is gaining access to Century Therapeutics' off-the-shelf CAR-T programs.

Sellers dominate the Street this week, but some healthcare stocks remain unaffected. Here are three to put atop your watchlist.

We think that Bristol Myers Squibb stock (NYSE: BMY) currently is a better pick compared to Pfizer stock (NYSE: PFE), given its better growth prospects and comparatively lower valuation of 3.0x traili

During the JPM Healthcare conference last week, Bristol Myers gave a bullish presentation outlining how it plans to grow revenues in the low double digits this decade.

January Buffett Dividend Dogs Show 3 Dandy Dynamutts

These potential corporate combinations would make a lot of sense.

2seventy bio Inc's (NASDAQ: TSVT) anti-BCMA CAR-T got axed as part of a corporate update. The treatment was under development in collaboration with Bristol Myers Squibb Co (NYSE: BMY).

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BioAtla, Bristol-Myers Squibb Announce Collaboration To Evaluate ADC-Opdivo Combo In Solid…

Biomica and a subsidiary of Evogene (EVGN) announce that the Israeli Ministry of Health (MoH) cleared the company to proceed with its Proof-of-Concept ((POC)), Phase I clinical trial

BMY appears ready to break out to new highs. BMY offers a significant dividend that is well covered.